Limits...
EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier.

Beltran B, Salas R, Quiñones P, Morales D, Hurtado F, Cotrina E, Riva L, Castillo J - Infect. Agents Cancer (2009)

Bottom Line: HTLV-1, on the other hand, induces T-cell dysfunction and B-cell proliferation.Finally, immunosenescence is characterized by T-cell dysregulation, decreased apoptosis and cytokine upregulation.Furthermore, the immunodeficiency caused by the viral infections and chemotherapy may have played a role in developing life-threatening infectious complications.

View Article: PubMed Central - HTML - PubMed

Affiliation: The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam Hospital, Providence, RI, USA. bgbrady@hotmail.com

ABSTRACT
The development of B-cell lymphomas has been seldom described in HTLV-1 carriers. We present the case of an elderly Peruvian HTLV-1 carrier who was diagnosed with EBV-positive diffuse large B-cell lymphoma. Despite an initial good response to therapy, patient died during treatment due to fatal Pneumocystis jirovecci pneumonia. EBV infection is characterized by B-cell lymphotropism and selective immunodeficiency. HTLV-1, on the other hand, induces T-cell dysfunction and B-cell proliferation. Finally, immunosenescence is characterized by T-cell dysregulation, decreased apoptosis and cytokine upregulation. In this elderly patient, the combination of EBV and HTLV-1 coinfection and immunosenescence may have played a role in the development of this aggressive diffuse large B-cell lymphoma. Furthermore, the immunodeficiency caused by the viral infections and chemotherapy may have played a role in developing life-threatening infectious complications.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical expression of MUM1. MUM1 is a plasma cell marker and, in DLBCL, is consistent with a non-germinal center subtype. DLBCL with a non-germinal center profile have been associated with worse survival (100×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2713202&req=5

Figure 2: Immunohistochemical expression of MUM1. MUM1 is a plasma cell marker and, in DLBCL, is consistent with a non-germinal center subtype. DLBCL with a non-germinal center profile have been associated with worse survival (100×)

Mentions: Automated immunohistochemistry studies were performed on paraffin-embedded tissue sections. The tumor cells were positive for CD20 (Dako, Carpinteria, CA; dilution 1:100; Figure 1), PAX5 (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 1:100) and MUM1 (Santa Cruz Biotechnology; dilution 1:200; Figure 2) and negative for CD10 (Novocastra; Newcastle upon Tyne, UK; dilution 1:10), BCL-6 (Dako; dilution 1:10), CD30 (Novocastra; dilution 1:100) and LMP-1 (Dako; dilution 1:100). Automated chromogenic in situ hybridization (CISH) for EBER was performed according to the manufacturer's protocol (Dako), and showed positive nuclear expression in tumoral cells (Figure 3).


EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier.

Beltran B, Salas R, Quiñones P, Morales D, Hurtado F, Cotrina E, Riva L, Castillo J - Infect. Agents Cancer (2009)

Immunohistochemical expression of MUM1. MUM1 is a plasma cell marker and, in DLBCL, is consistent with a non-germinal center subtype. DLBCL with a non-germinal center profile have been associated with worse survival (100×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2713202&req=5

Figure 2: Immunohistochemical expression of MUM1. MUM1 is a plasma cell marker and, in DLBCL, is consistent with a non-germinal center subtype. DLBCL with a non-germinal center profile have been associated with worse survival (100×)
Mentions: Automated immunohistochemistry studies were performed on paraffin-embedded tissue sections. The tumor cells were positive for CD20 (Dako, Carpinteria, CA; dilution 1:100; Figure 1), PAX5 (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 1:100) and MUM1 (Santa Cruz Biotechnology; dilution 1:200; Figure 2) and negative for CD10 (Novocastra; Newcastle upon Tyne, UK; dilution 1:10), BCL-6 (Dako; dilution 1:10), CD30 (Novocastra; dilution 1:100) and LMP-1 (Dako; dilution 1:100). Automated chromogenic in situ hybridization (CISH) for EBER was performed according to the manufacturer's protocol (Dako), and showed positive nuclear expression in tumoral cells (Figure 3).

Bottom Line: HTLV-1, on the other hand, induces T-cell dysfunction and B-cell proliferation.Finally, immunosenescence is characterized by T-cell dysregulation, decreased apoptosis and cytokine upregulation.Furthermore, the immunodeficiency caused by the viral infections and chemotherapy may have played a role in developing life-threatening infectious complications.

View Article: PubMed Central - HTML - PubMed

Affiliation: The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam Hospital, Providence, RI, USA. bgbrady@hotmail.com

ABSTRACT
The development of B-cell lymphomas has been seldom described in HTLV-1 carriers. We present the case of an elderly Peruvian HTLV-1 carrier who was diagnosed with EBV-positive diffuse large B-cell lymphoma. Despite an initial good response to therapy, patient died during treatment due to fatal Pneumocystis jirovecci pneumonia. EBV infection is characterized by B-cell lymphotropism and selective immunodeficiency. HTLV-1, on the other hand, induces T-cell dysfunction and B-cell proliferation. Finally, immunosenescence is characterized by T-cell dysregulation, decreased apoptosis and cytokine upregulation. In this elderly patient, the combination of EBV and HTLV-1 coinfection and immunosenescence may have played a role in the development of this aggressive diffuse large B-cell lymphoma. Furthermore, the immunodeficiency caused by the viral infections and chemotherapy may have played a role in developing life-threatening infectious complications.

No MeSH data available.


Related in: MedlinePlus